BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 23503753)

  • 21. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
    López RL; del Muro XG
    Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors.
    Blay JY; Pérol D; Le Cesne A
    Ann Oncol; 2012 Jul; 23(7):1659-65. PubMed ID: 22357253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
    Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
    Jpn J Clin Oncol; 2006 Nov; 36(11):704-11. PubMed ID: 17068083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
    Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Two cases of recurrent GIST successfully treated with imatinib mesylate at 100mg/day].
    Hanada N; Kawata K; Okamura S; Tomiyama N; Hori K
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):803-5. PubMed ID: 23863663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
    Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
    J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
    Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
    J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.
    Blay JY; Reichardt P
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):831-8. PubMed ID: 19496720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
    Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
    J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians.
    Durosinmi MA; Salawu L; Lawal OO; Ojo OS; Alatishe OI; Oyekunle AA; Bolarinwa RA; Adisa AO; Badmos K; Anomneze EE; Ayansanwo AO
    Afr J Med Med Sci; 2013 Dec; 42(4):325-32. PubMed ID: 24839736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety evaluation of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GISTs).
    Yang P; Chen B; Zhou Y; Wu XT
    Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):484-90. PubMed ID: 22889747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multidisciplinary care of gastrointestinal stromal tumour: a review and a proposal for a pre-treatment classification.
    Cananzi FC; Judson I; Lorenzi B; Benson C; Mudan S
    Eur J Surg Oncol; 2013 Nov; 39(11):1171-8. PubMed ID: 24063969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.
    Kanda T; Ishikawa T; Hirota S; Yajima K; Kosugi S; Ohashi M; Suzuki S; Mashima Y; Ajioka Y; Hatakeyama K
    Jpn J Clin Oncol; 2012 Jul; 42(7):578-85. PubMed ID: 22523393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
    Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK
    Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical analysis of imatinib in patients with advanced gastrointestinal stromal tumor].
    Zhang XH; Wu H; He YL; Ma JP; Chen CQ; Xu JB; Cai SR; Han FH; Zhan WH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Mar; 15(3):243-6. PubMed ID: 22454169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.
    Angelini S; Pantaleo MA; Ravegnini G; Zenesini C; Cavrini G; Nannini M; Fumagalli E; Palassini E; Saponara M; Di Battista M; Casali PG; Hrelia P; Cantelli-Forti G; Biasco G
    Pharmacol Res; 2013 Feb; 68(1):1-6. PubMed ID: 23127916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
    Jakob J; Mussi C; Ronellenfitsch U; Wardelmann E; Negri T; Gronchi A; Hohenberger P
    Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.